News ArticleAnthem Biosciences Posts Rs. 3,228.95 Million Profit for Half Year Ended September 30, 2026
Company reports Rs. 9,559.50 million revenue from operations and completes audit review with no material misstatements
Anthem Biosciences Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a half year profit of Rs. 3,228.95 million and revenue from operations of Rs. 9,559.50 million. The financial statements were reviewed by the Audit Committee and statutory auditors with no material misstatements noted.
Anthem Biosciences Limited
Financial Results
Anthem Biosciences Limited disclosed its unaudited standalone and consolidated financial results for Q2 and half year ended September 30, 2026, showing a profit of Rs. 3,228.95 million for the half year and revenue of Rs. 9,559.50 million from operations.
The Board of Directors approved the financial results during a meeting held on November 3, 2026, following a recommendation from the Audit Committee. The statutory auditors conducted a limited review and did not identify any material misstatements in the financial data presented.
For the quarter ended September 30, 2026, the company recorded revenue from operations of Rs. 5,721.08 million and a profit before tax of Rs. 3,041.17 million. The half year figures combine this with Rs. 3,838.42 million revenue and Rs. 1,363.60 million profit before tax recognised in the preceding quarter.
Expenses for the half year amounted to Rs. 6,087.68 million, covering material costs, employee benefits, finance costs, depreciation, and other operational expenses.
The company’s total comprehensive income for the half year stood at Rs. 3,193.68 million after tax and other comprehensive income adjustments.
The paid-up equity share capital as of September 30, 2026, was Rs. 1,127.06 million (nominal value Rs. 2 per share), with other equity reported at Rs. 30,723.58 million.
Highlights
- Half year revenue from operations: Rs. 9,559.50 million
- Profit for the half year: Rs. 3,228.95 million
- Quarterly revenue: Rs. 5,721.08 million (Q2 2026)
- Audit conducted by S.R. Batliboi & Associates LLP found no material misstatements
- Paid-up equity share capital: Rs. 1,127.06 million with nominal value Rs. 2 per share
Key Data Snapshot
What happened
- Anthem Biosciences Limited announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
- The Board of Directors approved the results on November 3, 2026, following review and recommendation by the Audit Committee.
- The statutory auditors, S.R. Batliboi & Associates LLP, completed a limited review without detecting any material misstatements.
Financial performance
- Revenue from operations was Rs. 5,721.08 million for Q2 and Rs. 9,559.50 million for the half year.
- Profit before tax was Rs. 3,041.17 million for Q2 and Rs. 4,404.77 million for the half year.
- Profit after tax for the half year was Rs. 3,228.95 million.
- Total comprehensive income for the half year amounted to Rs. 3,193.68 million after accounting for other comprehensive income.
- Employee benefits expense for the half year was Rs. 1,470.81 million.
- Total expenses for the half year were Rs. 6,087.68 million including material costs, finance, depreciation, and other expenses.
Regulatory and governance context
- Results are disclosed under SEBI LODR regulations as unaudited standalone and consolidated financial statements.
- The filing complies with Indian Accounting Standards (Ind AS) including Ind AS 34 for interim reporting.
- The company’s financial statements for the prior period were audited by predecessor auditors with unmodified opinion.
- The company maintains compliance with disclosure requirements, with financial results available on its website.
Highlights
- Half year revenue from operations: Rs. 9,559.50 million
- Profit for the half year: Rs. 3,228.95 million
- Quarterly revenue: Rs. 5,721.08 million (Q2 2026)
- Audit conducted by S.R. Batliboi & Associates LLP found no material misstatements
- Paid-up equity share capital: Rs. 1,127.06 million with nominal value Rs. 2 per share
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulation 30, 33, 47(1)
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Biocon Limited Reports Rs. 1,439 Million Profit for H1 FY2026-27; Appoints Mukesh Rathi as New CTO from January 2027
Biocon Limited declared its unaudited standalone financial results for the quarter and half-year ended September 30, 2026, reporting a profit of Rs. 1,439 million for the half-year. Alongside financial disclosure, the company announced a change in its senior management with the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as the new CTO starting January 1, 2027.
Read Full Story
Zydus Lifesciences Posts ₹10,541 Million Net Profit for Half Year Ending September 30, 2026
Zydus Lifesciences Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, recording a net profit of ₹7,145 million for Q2 and ₹10,541 million for the half year.
Read Full Story
Fractal Analytics Limited Reports Unaudited Q2 and H1 2026 Financial Results and Approves Winding Up of Analytics Vidhya Inc
Fractal Analytics Limited announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026. Additionally, the company's Board has approved winding up its step-down subsidiary Analytics Vidhya Inc., aiming to simplify group corporate structure and enhance operational efficiency without affecting ongoing business activities.
Read Full Story
